Study of ESBA105 Eye Drops in Healthy Subjects
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00671619|
Recruitment Status : Completed
First Posted : May 5, 2008
Last Update Posted : August 25, 2008
To evaluate the safety, tolerability and pharmacokinetics of ESBA105 administered topically to the eye for up to 28 days in healthy volunteers.
To determine the systemic exposure to ESBA105 upon single and repeated-dose topical application to the eye in healthy volunteers.
|Condition or disease||Intervention/treatment||Phase|
|Healthy||Drug: ESBA105||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||27 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||A Phase I, Randomized, Vehicle-Controlled, Double-Blind, Mono-Centric, Single and Repeated Dose, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ESBA105 Eye Drops in Healthy Subjects|
|Study Start Date :||April 2008|
|Actual Primary Completion Date :||July 2008|
|Actual Study Completion Date :||August 2008|
- Drug: ESBA105
- safety and tolerability [ Time Frame: several timepoints ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00671619
|Swiss Pharma Contract|